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Abstract
Background:  Recent meta-analyses have found a survival advantage with gemcitabine based
combinations over single agent gemcitabine in patients with advanced pancreatic cancer. There is
paucity of evidence in the form of direct head-to-head randomised controlled trials to determine
which combinations are to be preferred.
Method: Using the adjusted indirect comparison method proposed by Bucher et al, we have
assessed randomised controlled trials of four gemcitabine based combinations namely gemcitabine
plus a platinum compound or 5-fluorouracil or irinotecan or capecitabine.
Results: No particular combination was significantly superior to another, but the indirect evidence
suggests some important trends.
Conclusion: The strongest trends on indirect comparison are towards favouring gemcitabine plus
capecitabine or gemcitabine plus a platinum compound over gemcitabine plus irinotecan, and to a
lesser degree, over gemcitabine plus 5-fluorouracil.
Background
We have previously reported a systematic review and
meta-analysis of 19 studies evaluating gemcitabine based
combination chemotherapy compared to gemcitabine
alone [1] in patients with locally advanced and metastatic
pancreatic cancer. Overall survival was significantly better
for gemcitabine based combination chemotherapy (14
trials 4060 patients HR 0.91; 95% CI 0.85 to 0.97) com-
pared to single agent gemcitabine. A subgroup analysis
was performed, dividing the selected studies into four cat-
egories defined by the addition to gemcitabine of plati-
num agents or 5-fluorouracil (5FU) or irinotecan or
capecitabine (Table 1). The subgroup analysis found evi-
dence to suggest a survival advantage for gemcitabine
combined with either a platinum agent (HR 0.85; 95% CI
0.74 to 0.96) or capecitabine (HR 0.83; 95% CI 0.72 to
0.96), and insufficient evidence to support combinations
of gemcitabine with either 5FU (HR 0.98; 95% CI 0.86 to
1.11) or irinotecan (HR 1.01; 95% CI 0.84 to 1.22). These
analyses provide estimates of the survival advantage for
each combination compared to single agent gemcitabine
but do not provide estimates of the survival advantage for
Published: 8 July 2008
BMC Cancer 2008, 8:192 doi:10.1186/1471-2407-8-192
Received: 14 October 2007
Accepted: 8 July 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/192
© 2008 Sultana et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:192 http://www.biomedcentral.com/1471-2407/8/192
Page 2 of 5
(page number not for citation purposes)
each combination compared against another. To date,
there is only one phase II randomised controlled trial
[2,3] which directly compared different gemcitabine com-
binations in a head-to-head comparison. This was a small
study that directly compared only two gemcitabine based
combination chemotherapy regimens (gemcitabine plus
capecitabine versus gemcitabine plus oxaliplatin). In view
of the paucity of data directly comparing alternative gem-
citabine based combinations, we have attempted to
answer, for the first time, as to which combinations of
gemcitabine show more promise, an important clinical
question which no previous meta-analyses have
addressed.
Methods
We searched for direct comparisons of gemcitabine com-
binations, as well as used adjusted indirect comparisons
to evaluate the treatment effect across studies [3,4]
although this was not specified a priori. Illustration of
how the indirect comparison was obtained is given in the
following example. Suppose an intervention A was com-
pared against another intervention C in a randomised
controlled trial or meta-analysis, and likewise another
study (or meta-analysis) compared intervention B with
intervention C. Adjusted indirect comparison of treat-
ments A versus B was obtained as follows:
(1) The log hazard ratio of the adjusted indirect compari-
son for intervention A versus B was calculated using the
following formula:
log HRAB = log HRAC-log HRBC
where log HRAC was the log hazard ratio for the direct
comparison of intervention A versus C and log HRBC was
the log hazard ratio for the direct comparison of interven-
tion B versus C.
(2) The standard error for the log hazard ratio was
obtained using the calculation:
where SE(log HRAC) was the standard error of the log haz-
ard ratio for the direct comparison of intervention A ver-
sus C and SE(log HRBC) was the standard error of the log
hazard ratio for the direct comparison of intervention B
versus C.
The assumption of exchangeable treatment effects (treat-
ment effect observed in trials comparing A versus C is
assumed to be the treatment effect that would have been
observed in those trials comparing B versus C if treatment
A had been included in those trials and vice versa) across
comparisons was evaluated by assessing heterogeneity
across trials within each comparison and assessing com-
parability (methodological and clinical characteristics) of
all trials contributing to the indirect comparison.
SE HR SE HR SE HR AB AC BC (log ) (log ) (log ) =+
22
Table 1: List of included studies utilised in indirect comparison of gemcitabine based combination chemotherapy
Comparison Trial Group (number randomised)
Gemcitabine versus gemcitabine plus 
capecitabine
Cunningham 2005 (interim analyses) [12] Gemcitabine (n = 266)
Gemcitabine combination (n = 267)
Hermann 2005 [13,14] (analyses based on data from 
abstract published in 2005, plus extra data provided by 
trialist)
Gemcitabine (n = 159)
Gemcitabine combination (n = 160)
Scheithauer 2003 [15] Gemcitabine (n = 42)
Gemcitabine combination (n = 41)
Gemcitabine versus gemcitabine plus 5FU Berlin 2002 [8] Gemcitabine (n = 162)
Gemcitabine combination (n = 160)
Di Costanzo 2005 [10] Gemcitabine (n = 48)
Gemcitabine combination (n = 43)
Reiss 2005 [9] Gemcitabine (n = 236)
Gemcitabine combination (n = 230)
Gemcitabine versus gemcitabine plus 
platinum compound
Heinemann 2006 [16] Gemcitabine (n = 99)
Gemcitabine combination (n = 96)
Louvet 2005 [17] Gemcitabine (n = 163)
Gemcitabine combination (n = 163)
Poplin 2006 [18] Gemcitabine (n = 280)
Gemcitabine combination (n = 276)
Gemcitabine versus gemcitabine plus 
irinotecan
Rocha Lima 2004 [19] Gemcitabine (n = 180)
Gemcitabine combination (n = 180)
Stathopoulos 2005 [20,21] (analyses based on data from 
abstract published in 2005, plus extra data provided by 
trialist)
Gemcitabine (n = 69)
Gemcitabine combination (n = 57)BMC Cancer 2008, 8:192 http://www.biomedcentral.com/1471-2407/8/192
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Results
Adjusted indirect comparisons were computed for the fol-
lowing comparisons:
1. Gemcitabine plus a platinum agent versus gemcitabine
plus 5FU (GemPlat versus Gem5FU)
2. Gemcitabine plus a platinum agent versus gemcitabine
plus capecitabine (GemPlat versus GemCap)
3. Gemcitabine plus a platinum agent versus gemcitabine
plus irinotecan (GemPlat versus GemIrino)
4. Gemcitabine plus 5FU agent versus gemcitabine plus
capecitabine (Gem5FU versus GemCap)
5. Gemcitabine plus 5FU agent versus gemcitabine plus
irinotecan (Gem5FU versus GemIrino).
6. Gemcitabine plus capecitabine versus gemcitabine plus
irinotecan (GemCap versus GemIrino)
We did not find any one combination to be significantly
superior to others (Fig 1), but the indirect evidence sug-
gests some important trends, of which the strongest are
towards favouring gemcitabine plus capecitabine or gem-
citabine plus a platinum compound over gemcitabine
plus irinotecan (GemCap versus GemIrino HR 0.82, 95%
CI 0.65 to 1.04; GemPlat versus GemIrino HR 0.84, 95%
CI 0.67 to 1.06). Some advantage, to a lesser degree, was
suggested for these two combinations over gemcitabine
plus 5FU (Gem5FU versus GemCap HR 1.17, 95% CI 0.94
to 1.46; GemPlat versus Gem5FU HR 0.88, 95% CI 0.70
to 1.09). There was no evidence for heterogeneity within
the direct comparisons and no obvious inconsistency with
the assumption of exchangeable treatment effects.
Overall survival data was extracted from the single phase
II randomised trial to allow estimation of a HR (95% CI)
[5] for the direct comparison between GemOx and Gem-
Cap. There was no significant difference in overall survival
between the two combinations (HR 0.81, 95% CI 0.56 to
1.18) on direct head-to-head comparison [2] as well as on
computing this combining the results of both the direct
and indirect comparisons (HR 0.94, 95% CI 0.79 to 1.12)
using random effects analysis.
Discussion
In a situation wherein two drugs A and B have, in ran-
domised controlled trials, shown to be effective in com-
parison to a placebo or common standard, but direct
comparison between A and B is not available, indirect
comparison can be used [4]. The use of a simple indirect
comparison has the limitation that the difference detected
may not be a true difference, but instead be attributable to
variations in patient characteristics and other prognostic
factors in the different trials. An adjusted indirect compar-
ison method was proposed by Bucher et al, and this
method maintains the randomisation of the originally
assigned patients while calculating the magnitude of the
treatment effect.
Song et al assessed the comparability of indirect with the
direct head to head comparison in the setting of clinical
Indirect comparison between different gemcitabine-based combination chemotherapy regimens Figure 1
Indirect comparison between different gemcitabine-based combination chemotherapy regimens.BMC Cancer 2008, 8:192 http://www.biomedcentral.com/1471-2407/8/192
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trials dealing with antimicrobial prophylaxis in colorectal
cancer, and later using a sample of 44 comparisons from
28 systematic reviews [3,6]. Compared with direct esti-
mates, the adjusted indirect estimates were less likely to be
statistically significant. Adjusted indirect comparisons
usually but not always agree with the results of head to
head randomised trials. When there is no or insufficient
direct evidence from randomised trials, the adjusted indi-
rect comparison can provide useful or supplementary
information on the relative efficacy of competing inter-
ventions. The results of adjusted indirect comparisons
should be interpreted with caution however and the inter-
nal and external validity of the trials involved examined
carefully, to investigate potential causes of discrepancy.
This adjusted indirect comparison of gemcitabine-based
combination chemotherapy is very important clinically as
there is paucity of evidence comparing these combina-
tions and this is the first time hazard ratios have ever been
calculated for these pairwise comparisons. The only ran-
domised trial comparing gemcitabine combinations was a
phase II multicentre study that compared capecitabine
plus oxaliplatin(CapOx) versus capecitabine plus gemcit-
abine (CapGem) versus gemcitabine plus oxaliplatin
(mGemOx) [2]. There was no significant difference in the
primary end point of progression free survival [median
progression free survival time (p = 0.56) and progression
free survival rates (p = 0.67)] and overall survival (Gem-
Cap versus GemOx HR 0.81; 95% CI 0.56–1.18). Grade 3/
4 haematological toxicities were seen more often in the
gemcitabine containing arms.
Although indirect evidence may not be as reliable as evi-
dence from a randomised head to head comparison, these
analyses show some interesting trends that could be used
to direct future research priorities. The assumption of
exchangeable treatment effects would seem reasonable for
these comparisons which add strength to the clinical
interpretation and conclusions. In particular, trends sug-
gest that gemcitabine plus irinotecan may be the least
effective of the combinations examined. The lack of signif-
icant differences on indirect comparison is probably due
to the already highlighted observation that this method
tends to yield results that are less statistically significant
than in a direct comparison [6]. Indeed, it can be shown
that one directly randomised trial is as precise as an indi-
rect comparison based on four randomised trials of the
same size.
A note-worthy observation on indirect comparison was
that overall survival with gemcitabine combined with the
fluoropyrimidine 5FU was inferior (though not statisti-
cally significant) to gemcitabine plus another fluoropyri-
midine capecitabine (HR 1.17). A likely explanation is
that capecitabine, an oral prodrug of 5FU, has the advan-
tage of an element of tumour targeting, leading to
enhanced selectivity and better tolerability [7]. The higher
levels of thymidine phorphorylase (the final requisite
enzyme for conversion of capecitabine to 5FU) observed
in tumours compared to normal tissue may account for
the improved targeting. Another possibility is the mode of
delivery of 5FU versus capecitabine. The 5FU trials have
involved bolus 5FU schedule [8] or 24 hour infusion [9],
with the exception of one trial where 5FU was given by
continuous infusion [10]. In contrast, the administration
of capecitabine is more analogous to the delivery of 5FU
by continuous protracted venous infusion, with the added
ease of oral administration.
In the light of level I evidence demonstrating that gemcit-
abine based combinations have a modest survival advan-
tage over single agent gemcitabine, the current study
indicates which combinations may be more efficacious.
The findings of our original meta-analyses, as well as the
trends observed on our adjusted indirect comparisons
support the use of gemcitabine in combination with
either capecitabine or a platinum compound in clinical
practice. Future randomised controlled trials will now
likely to be centred on the exploitation of novel targets or
biology (such as Telovac) [11] in this chemo-resistant can-
cer, probably on a cytotoxic backbone of a gemcitabine
combination.
Conclusion
Adjusted indirect comparison of randomised controlled
trials examining gemcitabine in combination with
capecitabine, platinum based compounds, 5FU and iri-
notecan reveal trends towards favouring gemcitabine plus
capecitabine or gemcitabine plus a platinum compound
over gemcitabine plus irinotecan and to a lesser degree,
over gemcitabine plus 5-fluorouracil. Future trials will
now likely to be centred on the exploitation of novel tar-
gets or biology, probably on a cytotoxic backbone of a
gemcitabine combination.
Abbreviations
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